Overview

A Study to Assess the Safety, Tolerability and Pharmacokinetics of Guselkumab Following a Single Intravenous Administration in Healthy Japanese Participants

Status:
Completed

Trial end date:
2018-10-25

Target enrollment:

Participant gender:

Summary

The purpose of this study is to assess the safety and tolerability of guselkumab following single-dose intravenous (IV) infusion in Japanese healthy male participants.

Phase:

Phase 1

Details

Lead Sponsor:

Janssen Pharmaceutical K.K.

Treatments:

Antibodies, Monoclonal